长城医药科技六个月持有混合C(011674)利润分配表
|
2024-12-31 |
2024-06-30 |
2023-12-31 |
2023-06-30 |
收入 |
-86,209,796.67 |
-101,761,561.26 |
-28,801,260.76 |
-11,503,867.79 |
利息合计 |
409,518.08 |
240,463.24 |
663,119.58 |
343,777.55 |
其中:存款利息收入 |
409,518.08 |
240,463.24 |
663,119.58 |
343,777.55 |
债券利息收入 |
- |
- |
- |
- |
资产支持证券利息收入 |
- |
- |
- |
- |
买入返售金融资产收入 |
- |
- |
- |
- |
投资收益合计 |
-46,536,466.28 |
-43,150,061.22 |
-65,518,136.58 |
-28,749,002.09 |
其中:股票投资收益 |
-50,631,654.85 |
-46,402,404.28 |
-71,541,371.86 |
-33,010,884.17 |
基金投资收益 |
- |
- |
- |
- |
债券投资收益 |
149,372.64 |
77,884.48 |
766,291.61 |
119,777.00 |
资产支持证券投资收益 |
- |
- |
- |
- |
衍生工具收益 |
- |
- |
- |
- |
股利收益 |
3,945,815.93 |
3,174,458.58 |
5,256,943.67 |
4,142,105.08 |
基金分红收益收益 |
- |
- |
- |
- |
公允价值变动收益 |
-40,082,848.47 |
-58,851,963.28 |
36,053,756.24 |
16,901,356.75 |
其他收入 |
- |
- |
- |
- |
费用 |
6,319,482.64 |
3,331,608.84 |
10,014,480.28 |
5,811,772.18 |
管理人报酬 |
5,091,437.76 |
2,689,468.37 |
8,194,393.76 |
4,778,637.97 |
基金托管费 |
848,573.07 |
448,244.83 |
1,365,732.25 |
796,439.62 |
销售服务费 |
169,505.85 |
89,797.98 |
239,266.44 |
130,427.56 |
交易费用 |
- |
- |
- |
- |
利息支出 |
- |
- |
- |
- |
其中:卖出回购金融资产支出 |
- |
- |
- |
- |
其他费用 |
209,964.89 |
104,097.55 |
215,085.58 |
106,266.38 |
利润总额 |
-92,529,279.31 |
-105,093,170.10 |
-38,815,741.04 |
-17,315,639.97 |